Emcure Pharmaceuticals Announces Strong Q4 and Full Year FY26 Results, Recommends Dividend

Emcure Pharmaceuticals Announces Strong Q4 and Full Year FY26 Results, Recommends Dividend​

Emcure Pharmaceuticals Limited announced its consolidated financial results for the fourth quarter and full year ended March 31, 2026. The company reported robust financial performance for the fiscal year, noting a milestone of over US$1 billion in revenue.

Speaking on the announcement, Satish Mehta, CEO and Managing Director of Emcure Pharmaceuticals Ltd., noted that in FY26, the company delivered strong financial growth, attributing the performance to robust momentum in international markets and steady growth in the domestic business.

The company's financial performance for the full year ended March 31, 2026, showed significant year-over-year growth across multiple metrics.

Financial Performance Highlights (FY26)​

The reported figures highlight the growth achieved across the board:


Quarter 4 (Q4) FY26 Results:
The fourth quarter saw continued growth, with revenue from operations reaching ₹2,470 Cr (up 16.7% YoY). EBITDA stood at ₹485 Cr, marking a 24.5% increase year-over-year.


International business sales, contributing ₹5,177 Cr for the full year, showed strong momentum, increasing 22.2% year-over-year.

Corporate Governance and Appointments​

On May 5, 2026, the Board of Directors of Emcure Pharmaceuticals Limited transacted and recommended key corporate decisions:

Dividend Recommendation
The Board recommended a final dividend of Rs. 3.60/- (Rupees Three and Sixty Paise only) per equity share of Rs. 10/- (Rupees Ten only) each for the financial year ended March 31, 2026. This payment is subject to the approval of the Members of the Company at the ensuing Annual General Meeting.

Key Management Personnel Appointments
The Board of Directors also approved the re-appointment of senior management:

• Mr. Satish Mehta was re-appointed as the Managing Director of the Company for a further period of five years, effective from April 01, 2027, subject to Members' approval.
• Dr. Mukund Gurjar was re-appointed as a Whole-time Director for a further period of one year, commencing from August 28, 2026, subject to Members' approval.

Financial Position Snapshot​

The comprehensive financial statements for the year ended March 31, 2026, reflect the company's operational scale.

Consolidated Balance Sheet Data (in million):


The company's overall commitment to delivering sustainable, above-industry growth remains a key focus, with continued expansion strategies centered on in-licensing, minority buyouts, and bolt-on acquisitions in regions like the UK and Canada.

EMCURE Stock Price Movement​

As of 2:47 PM, shares of Emcure Pharmaceuticals Limited are slipping by 3.55% in live trading, currently hovering at ₹1729.6. The stock shed ₹63.60 on a volume of 491,952 shares, notably pulling back after having reached its 52-week high of ₹1830.